Digital Neuro Biomarkers Market Size:
The Digital Neuro Biomarkers Market was valued at USD 538.96 million in 2023 and is expected to reach USD 4592.14 million by 2032, growing at a CAGR of 25.96% from 2024-2032.
The market for digital neuro biomarkers is growing exponentially as a result of increasing neurological disorders, advancements in technology, and the growing demand for personalized healthcare solutions. These are essentially used for the diagnosis, monitoring, and tracking of the progression of various neurological conditions such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, and epilepsy. Furthermore, real-time data as well as deeper insights into a patient's health condition are fuelling the adoption of digital neuro biomarkers across health care settings.
The main cause that is driving market growth is due to the rise in neurological disorders. According to the World Health Organization, diseases related to this area are one of the highest causes of disablement in people worldwide. The World Health Organization (WHO) reports that approximately 24 million people globally are diagnosed with Alzheimer's disease and other forms of dementia. However, the total number of individuals affected by dementia is believed to be significantly higher, with over 55 million people impacted worldwide.
Advances in wearables, mobile applications, and artificial intelligence also play a huge role in driving market expansion. Wearables, such as smartwatches and fitness bands, integrated with digital neuro biomarkers, track neurological conditions in real time. A good example would be Revibe Technologies' wearable reminder system has improved attention span and on-task behavior among children suffering from ADHD to a great extent.
Mobile-based applications are also anticipated to grow in leaps and bounds as a result of increased usage of smartphones, health-oriented applications, and the ability to collect high-frequency data inexpensively, allowing patients to easily monitor the disease's progression from home and reduce symptoms. Among the main recent developments are collaborations and partnerships among key players in advancing digital biomarker solutions. For instance, in May 2024, RCSI teamed up with Head Diagnostics for clinical trials that aim to improve how multiple sclerosis is judged through digital biomarkers. Therefore, all these developments and updates are anticipated to continue driving the growth of the market over the following years.
Market Dynamics
Drivers
The rising prevalence of neurological disorders is the key driver expected to drive the growth of the digital neuro biomarker market.
Conditions like Alzheimer's and Parkinson's disease are increasingly common as the global population ages, and neurological disease claims nearly 6.8 million lives each year, according to the World Health Organization (WHO). For example, a 2022 report from the Parkinson’s Foundation found that roughly 90,000 new cases of Parkinson’s disease are diagnosed each year in the U.S. That’s roughly a 50 percent jump from prior estimates. The incidence of these diseases is increasing, leading to a growing demand for early diagnosis, monitoring, and management, which could be solved by digital neuro biomarkers. The downstream biomarkers have the added benefit of teaching us more continuous data points, giving us live analytics on their health status, and are instrumental for individualized medication regimes and preemptive treatments.
Advanced wearable devices and mobile health applications are accelerating the adoption of digital neuro biomarkers.
Wearables, such as smartwatches and fitness trackers, are increasingly integrated with neuro biomarkers to monitor cognitive and neurological conditions in real time. Mobile applications that enable real-time monitoring of neurological health also play a key role in the growth of this market. These apps collect high-frequency data at a lower cost and are easily accessible to patients. For example, the virtual reality platform NeuroTrainer has improved concentration and cognitive function, which has already had positive effects on at-risk students. Integration of wearables with mobile applications has made the management and monitoring of neurological conditions more accessible and outside traditional clinical settings, increasing market demand further.
Restraint
One of the key restraints for the digital neuro biomarkers market is the regulatory challenges and concerns around data privacy.
The particular biomarker essentially collects health-related data from an individual which happens to include their cognitive as well as neurological profile, appropriate compliance with certain norms in almost every region has become inevitable. The regulatory approval process for medical devices and digital health technologies is quite complex and time-consuming, hence delaying product development and market entry. For instance, in the U.S., medical devices like those with a digital biomarker have to go through FDA approval, which calls for extensive clinical trials and proof of safety and efficacy.
Besides, collecting, storing, and transferring personal health data has also created critical concerns about data security and privacy. Due to stringent data protection regulations like GDPR in Europe and HIPAA in the United States, companies have to make sure that their digital solutions meet the criteria for not violating the regulation in any form. The complexities that will be associated with compliance with regulatory and privacy standards might delay the fast-paced adoption and scaling of neuro biomarkers in digital media across different geographical locations.
Segment Analysis
By Type
The wearable segment dominated the market with the largest market share of 38% in 2023. That's because consumers are demanding more wearables that enable them to monitor data on the go. The rise in the field of wearables and smart devices is thus consistently fueling the growth of the segment. The Wearable Reminder System, developed by Revibe Technologies, is designed specifically to improve focus in children with attention deficit hyperactivity disorder (ADHD) by tracking on-task behavior and providing coaching reminders when a child is inattentive. In one initial trial, results showed a 25-minute increase in attention span and a 19% increase in on-task behavior over three weeks of use.
The mobile-based application segment is projected to witness the fastest CAGR during the forecast period. The emergence of this segment is driven primarily by the rapid penetration of smartphones and the improvement of wearable technologies forming a perfect platform for health applications. These applications enable real-time monitoring of neurological conditions, providing an easy and cost-effective method to Attain high-frequency data critical for symptom management and disease progression monitoring. To illustrate, the virtual reality platform NeuroTrainer originally designed as a sports training tool will be adapted to improve focus and attention, and therefore academic performance, among at-risk middle and high school students.
By Clinical Practice
The Diagnostic Psychiatric Digital Biomarkers segment dominated the market with the largest market share of 28% in 2023. Diagnostic biomarkers are essential in the identification or confirmation of a disease and/or disease subtype, which is vital for diagnosis. The subtypes of the disease can be defined further by biomarkers by improving their classification, hence improving the diagnostics of the patients. The market presence of key players will increase with the launch of new products in this segment. For instance, in May 2024, RCSI collaborated with Head Diagnostics, a company based in Dublin, to conduct a clinical trial on improving the assessment and monitoring of multiple sclerosis. The study examines the possibility of new digital biomarkers in monitoring the disease. In June 2022, Rune Labs, a precision neurology company, announced that its StrivePD software platform for Parkinson's disease was granted 510(k) clearance by the U.S. FDA, which allows the collection of patient symptom data through Apple Watch measurements.
Monitoring Psychiatric Digital Biomarkers is expected to grow at the fastest rate during the forecast period due to monitoring digital biomarkers provides a real-time, all-encompassing view of a patient's health, which is crucial for delivering personalized healthcare. With the possibility of continuous monitoring of mobility and other health parameters beyond the walls of the clinics, digital biomarkers can reveal information that gives instantaneous insight into the patient's state of health.
Regional Analysis
In 2023, North America dominated the market for digital neuro biomarkers with a share of 35% of the total market. Rising demand for diagnosis of neurological conditions has been an important factor fueling this growth. The high prevalence of neuro disorders, a rapidly aging population, large expenditure on neurological treatment within healthcare settings, and a positive reimbursement policy toward neuro-diagnostic procedures.
The Asia Pacific digital neuro biomarkers market is expected to show the fastest growth throughout the forecast period. The market is growing due to various strategies adopted by key players, such as launching products for neurological conditions, forming partnerships, and engaging in mergers and acquisitions. For instance, Lumos Labs is using a massive dataset from tens of millions of adults who have completed billions of cognitive tasks on its Lumosity platform to enhance cognitive performance through digital interventions. This data is being used to develop digital biomarkers that are meant to predict, diagnose, and monitor cognitive issues related to conditions such as ADHD, multiple sclerosis, and many others.
Key Market Players
Altoida Inc. (Neuro Motor Index, Digital Cognitive Assessment Platform)
Koneksa (Koneksa Compare, Mobile Neurocognitive Tests)
Biogen Inc. (MS Performance Test, CogEval)
Roche (Navify Algorithm Suite, Remote Patient Monitoring)
NeuraMetrix (Typing Biometrics, NeuraMetrix Dashboard)
Merck KGaA (Syntropy, Digital Biomarker Discovery)
Linus Health (Digital Cognitive Assessment, Brain Health Platform)
Neurotrack Technologies, Inc. (Memory Health Program, Eye Tracking Assessment)
Empatica Inc. (EmbracePlus, Aura)
Eyenuk (EyeArt AI System, EyeMark)
BioSensics (PAMSys, LEGSys)
ActiGraph LLC (CentrePoint Insight Watch, ActiLife Software)
Aural Analytics (Speech Vitals, A2E Platform)
Sonde Health, Inc. (Sonde Mental Fitness, Sonde Respiratory
Quibim (QP-Brain, QP-Prostate)
IXICO plc (TrialTracker, Assessa)
Huma (Disease Agnostic Platform, Digital Biomarker Discovery)
Feel Therapeutics (Feel Emotion Sensor, Digital Therapeutics Platform)
Brainomix (e-Stroke Suite, e-CTA)
Kinsa Inc. (Kinsa Smart Thermometers, HealthWeather)
Key suppliers
These suppliers enable the manufacturing, functionality, and scalability of innovative digital neuro biomarker solutions.
Intel Corporation Suppliers
Texas Instruments Suppliers
STMicroelectronics Suppliers
Qualcomm Technologies, Inc. Suppliers
Bosch Sensortec Suppliers
Honeywell International Inc. Suppliers
Medidata Solutions Suppliers
Flex Ltd. Suppliers
Garmin Health Suppliers
Analog Devices, Inc. Suppliers
Recent Developments
March 2024: Indivi, a leading MedTech company based in Basel, Switzerland, announced a strategic collaboration with Biogen to drive innovation in digital health technologies and develop advanced digital biomarkers for Parkinson’s disease. As part of this agreement, Biogen has licensed its Konectom platform to Indivi. Konectom, a cutting-edge smartphone-based digital biomarker system, facilitates remote neurological function assessments, enabling precise and frequent tracking of disease progression.
March 2024: Merck has joined the LEARNS observational study, aimed at exploring the role of digital biomarkers in assessing and predicting the progression of Parkinson’s disease. The partnership, led by healthcare technology company Koneksa, grants Merck real-time access to comprehensive data and results throughout the study. This initiative underscores Merck’s commitment to advancing research in neurodegenerative diseases.
February 2024: Koneksa, a leader in digital biomarker technology, announced the enrollment of the first patient in the LEARNS study, an observational research initiative. The study aims to evaluate the reliability and responsiveness of digital biomarkers over time using mobile and wearable-based assessments. By improving signal detection, the study seeks to support the development of disease-modifying therapies for neurodegenerative conditions, including Parkinson’s disease.
July 2023: Linus Health, a pioneer in digital health solutions for the early detection of Alzheimer’s and other dementias, shared results from eight new studies at the 2023 Alzheimer’s Association International Conference. The findings validate the company’s AI-enhanced digital cognitive assessment technology, demonstrating its superior accuracy compared to traditional paper-based tests in detecting mild cognitive impairment (MCI) and dementia. Additionally, the studies highlight the seamless transition of Linus Health’s solutions from research settings to clinical practice, reinforcing their practical application in real-world healthcare.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 538.96 million |
| Market Size by 2032 | US$ 4592.14 million |
| CAGR | CAGR of 25.96% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Mobile-based Applications, Wearable, Sensors, Others) • By Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers, Others) • By End Use (Healthcare Companies, Healthcare Providers, Payers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Altoida Inc., Koneksa, Biogen Inc., Roche, NeuraMetrix, Merck KGaA, Linus Health, Neurotrack Technologies, Inc., Empatica Inc., Eyenuk, BioSensics, ActiGraph LLC, Aural Analytics, Sonde Health, Inc., Quibim, IXICO plc, Huma, Feel Therapeutics, Brainomix, Kinsa Inc., and other players. |
| Key Drivers | •The rising prevalence of neurological disorders is the key driver expected to drive the growth of the digital neuro biomarker market. •Advanced wearable devices and mobile health applications are accelerating the adoption of digital neuro biomarkers. |
| Restraints | •One of the key restraints for the digital neuro biomarkers market is the regulatory challenges and concerns around data privacy. |
Ans- The Digital Neuro Biomarkers Market was valued at USD 538.96 million in 2023 and is expected to reach USD 4592.14 million by 2032.
Ans – The Digital Neuro Biomarkers Market's CAGR rate from 2024-2032 is 25.96%.
Ans- The wearable denature segment dominated the market by 38%
Ans- North America held the largest revenue share by 35%.
Ans- Asia Pacific is the fastest-growing Digital Neuro Biomarkers Market region.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Device Volume, by Region (2020-2032)
5.3 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket) (2023)
5.4 Research and Development Investment Trends (2023)
5.5 Adoption Rates in Clinical vs. Consumer Markets (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Digital Neuro Biomarkers Market Segmentation, by Type
7.1 Chapter Overview
7.2 Mobile-based Applications
7.2.1 Mobile-based Applications Market Trends Analysis (2020-2032)
7.2.2 Mobile-based Applications Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Sensors
7.3.1 Sensors Market Trends Analysis (2020-2032)
7.3.2 Sensors Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Others
7.4.1 Others Market Trends Analysis (2020-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
8. Digital Neuro Biomarkers Market Segmentation, by Clinical Practice
8.1 Chapter Overview
8.2 Diagnostic Psychiatric Digital Biomarkers
8.2.1 Diagnostic Psychiatric Digital Biomarkers Market Trends Analysis (2020-2032)
8.2.2 Diagnostic Psychiatric Digital Biomarkers Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Monitoring Psychiatric Digital Biomarkers
8.3.1 Monitoring Psychiatric Digital Biomarkers Market Trends Analysis (2020-2032)
8.3.2 Monitoring Psychiatric Digital Biomarkers Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Predictive and Prognostic Psychiatric Digital Biomarkers
8.4.1 Predictive and Prognostic Psychiatric Digital Biomarkers Market Trends Analysis (2020-2032)
8.4.2 Predictive and Prognostic Psychiatric Digital Biomarkers Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Digital Neuro Biomarkers Market Segmentation, by End User
9.1 Chapter Overview
9.2 Healthcare companies
9.2.1 Healthcare companies Market Trends Analysis (2020-2032)
9.2.2 Healthcare companies Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Healthcare Providers
9.3.1 Healthcare Providers Market Trends Analysis (2020-2032)
9.3.2 Healthcare Providers Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Payers
9.4.1 Payers Market Trends Analysis (2020-2032)
9.4.2 Payers Market Size Estimates and Forecasts to 2032 (USD Million)
9.5 Others
9.5.1 Others Market Trends Analysis (2020-2032)
9.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Digital Neuro Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.4 North America Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.2.5 North America Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.6.2 USA Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.2.6.3 USA Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.7.2 Canada Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.2.7.3 Canada Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.8.2 Mexico Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.2.8.3 Mexico Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.6.2 Poland Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.1.6.3 Poland Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.7.2 Romania Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.1.7.3 Romania Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.8.2 Hungary Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.1.8.3 Hungary Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.9.2 Turkey Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.1.9.3 Turkey Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.4 Western Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.5 Western Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.6.2 Germany Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.6.3 Germany Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.7.2 France Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.7.3 France Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.8.2 UK Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.8.3 UK Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.9.2 Italy Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.9.3 Italy Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.10.2 Spain Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.10.3 Spain Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.13.2 Austria Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.13.3 Austria Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Digital Neuro Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.4 Asia Pacific Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.5 Asia Pacific Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.6.2 China Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.6.3 China Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.7.2 India Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.7.3 India Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.8.2 Japan Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.8.3 Japan Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.9.2 South Korea Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.9.3 South Korea Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.10.2 Vietnam Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.10.3 Vietnam Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.11.2 Singapore Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.11.3 Singapore Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.12.2 Australia Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.12.3 Australia Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Digital Neuro Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.4 Middle East Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.1.5 Middle East Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.6.2 UAE Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.1.6.3 UAE Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.7.2 Egypt Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.1.7.3 Egypt Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.9.2 Qatar Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.1.9.3 Qatar Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.4 Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.2.5 Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.6.2 South Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.2.6.3 South Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Digital Neuro Biomarkers Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.4 Latin America Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.6.5 Latin America Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.6.2 Brazil Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.6.6.3 Brazil Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.7.2 Argentina Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.6.7.3 Argentina Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.8.2 Colombia Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.6.8.3 Colombia Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Digital Neuro Biomarkers Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Digital Neuro Biomarkers Market Estimates and Forecasts, by Clinical Practice (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Digital Neuro Biomarkers Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11. Company Profiles
11.1 Altoida Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Koneksa
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Biogen Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Roche
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 NeuraMetrix
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Linus Health
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Merck KGaA
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Empatica Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Eyenuk
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 BioSensics
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Type
Mobile-based Applications
Wearable
Sensors
Others
By Clinical Practice
Diagnostic Psychiatric Digital Biomarkers
Monitoring Psychiatric Digital Biomarkers
Predictive and Prognostic Psychiatric Digital Biomarkers
Others
By End Use
Healthcare companies
Healthcare Providers
Payers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization to meet the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Biobanking Market size was valued at USD 76.68 billion in 2023, and is expected to reach USD 151.11 billion by 2031 and grow at a CAGR of 8.85% over the forecast period 2024-2031.
The Bioremediation Market size was estimated at USD 14.95 billion in 2023 and is expected to reach USD 34.27 billion by 2032 with a growing CAGR of 9.69% during the forecast period of 2024-2032.
The Track and Trace Solutions Market Size was valued at USD 3.51 billion in 2022, and is expected to reach USD 14.21 billion by 2030 and grow at a CAGR of 19.1% over the forecast period 2023-2030.
The Scoliosis Management Market size was USD 3060.51 Million in 2023 and is expected to Reach USD 4356.06 Million by 2032 and grow at a CAGR of 4% over the forecast period of 2024-2032.
The Venous Thromboembolism Treatment Market Size was valued at USD 1.05 Bn in 2023, and is expected to reach USD 2.13 Bn by 2032, and grow at a CAGR of 8.50% Over the Forecast Period of 2024-2032.
The Oncology Information System Market Size was valued at USD 3.36 billion in 2023, and is expected to reach USD 6.13 billion by 2031, and grow at a CAGR of 7.8% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
